Print Print Send link Bookmark and Share

Molecular diagnostic and immunotechnology


VTT develops biomolecular recognition and antibody engineering for diagnostic, therapeutic and analytical applications as well as for biomarker discovery. Antibodies are today the most attractive binding since they can be generated against virtually any molecule with affinity constants in the nanomolar range. Antibodies towards allergens, cell receptors, drugs, toxins and other small molecules suitable for new diagnostic and therapy concepts are generated using phage display and high throughput screening methods. VTT’s functional, existing antibody phage display libraries can be used for the rapid isolation of different binding specificities. Antibody engineering can be exploited to improve the properties of the isolated antibodies e.g. for immunoassay applications.

Molecular diagnostic has special focus on anti-hapten antibodies and the development of antibody-based micro- and nanotechnology applications.

In the field of immunotechnology VTT focuses on allergy research and the development of diagnostic and therapeutic antibodies especially using patient-specific libraries.


The novel biomarkers identified by genomics, proteomics and metabolomics provide advanced diagnostics and therapy enabling more effective and personalized prognosis and treatment of diseases. This creates a challenge for the efficient and fast generation of specific antibodies utilised for sensitive detection and imaging of these biomarkers. Isolation of different binding specificities can be carried out simultaneously from antibody gene libraries using multiplex library selection and screening procedures.


We offer the construction of antibody phage libraries from immune, non-immune and patient-derived sources. The isolation of antibodies can be carried out by in vitro and in vivo selection or by direct screening techniques. The large-scale production of active recombinant antibody fragments is performed in Escherichia coli. Biochemical and immunological methods are utilized for the characterization of the binding properties. The affinity, specificity, stability and labelling efficiency of antibodies can be tailored by mutagenesis and DNA shuffling methods. Fusions with peptide tags having different immobilisation or labelling properties can be done to enhance their applicability.

  • Construction of antibody phage display libraries
  • Isolation of antibodies from phage display libraries e.g. by in vitro high-throughput selection and screening by a robotic workstation
  • Large-scale production of antibody fragments in E.coli
  • Characterization of antibody binding properties
  • Improvement of antibody properties


Our recombinant antibody technology provides

  • Isolation of recombinant antibodies in a reasonable time span
  • Generation of antibodies against conserved, toxic and self-antigens
  • Tailor-made antibodies for desired applications
  • Cost-effective production of antibody fragments

Additional information

Marja-Leena Laukkanen
Senior Scientist
+358 20 722 5142

Tarja Nevanen
Principal Scientist, Team Leader
+358 20 722 5967

Petri Saviranta
Senior Scientist, Team Leader
+358 20 722 2831

Kristiina Takkinen
Research Professor
+358 20 722 5106